Analysis Of Income And Expense [Abstract]

STADA Arzneimittel AG - Filing #6743034

Concept 2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Dividend income
- EUR
7,000 EUR
Revenue
3.249.451 EUR
3.010.315 EUR
Material income and expense [abstract]
Research and development expense
86,513 EUR
84,907 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
72,901 EUR
127,191 EUR
Income tax relating to exchange differences on translation of foreign operations and hedges of net investments in foreign operations included in other comprehensive income [abstract]
Income tax relating to exchange differences on translation of foreign operations included in other comprehensive income
215,000 EUR
741,000 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of associates and joint ventures accounted for using equity method
269,000 EUR
93,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
344,698 EUR
57,611 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
327,612 EUR
43,210 EUR
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests
17,086 EUR
14,401 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.